FIELD: biotechnology.
SUBSTANCE: invention relates to the methods of the production of T-cells, according to which the stages of activation, stimulation, transduction using a viral vector containing a polynucleotide encoding a chimeric antigen receptor (CAR) to the B-cell maturation antigen (BCMA), as well as Cultivation of transduced T-cells for proliferation is performed in the presence of a phosphatidyl-inositol 3-kinase (PI3K) inhibitor. The use of this inhibitor increases the expression of CD62L.
EFFECT: T-cells obtained in this way can be used in adaptive therapy.
15 cl, 6 dwg, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IMPROVED COMPOSITIONS BASED ON T-CELLS | 2015 |
|
RU2719030C2 |
| COMBINATION THERAPY FOR THE TREATMENT OF BCMA-RELATED CANCER AND AUTOIMMUNE DISORDERS | 2018 |
|
RU2799762C2 |
| IMPROVED METHODS FOR PRODUCING ADOPTIVE CELL THERAPY AGENTS | 2015 |
|
RU2741899C2 |
| CHIMERIC ANTIGEN RECEPTORS FOR BCMA AND THEIR USE | 2019 |
|
RU2785658C2 |
| CANCER TREATMENT WITH CHIMERIC CD33 ANTIGEN RECEPTOR | 2015 |
|
RU2747384C2 |
| CHIMERIC ANTIGEN RECEPTORS WITH MUTATED CD28 COSTIMULATION DOMAINS | 2018 |
|
RU2800922C2 |
| CHIMERIC ANTIGENIC RECEPTORS WITH MND-PROMOTER | 2015 |
|
RU2708311C2 |
| TREATING A MALIGNANT TUMOR USING A CHIMERIC ANTIGEN CD19 RECEPTOR | 2015 |
|
RU2718542C2 |
| METHODS OF EX VIVO EXPANSION OF NATURAL KILLER CELLS AND THEIR USE | 2019 |
|
RU2814083C2 |
| CHIMERIC ANTIGENIC RECEPTORS WITH MND PROMOTER | 2015 |
|
RU2799573C2 |
